These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21906494)

  • 1. DRESS syndrome associated with raltegravir.
    Zhang KS; Modi GM; Hsu S
    Dermatol Online J; 2011 Aug; 17(8):14. PubMed ID: 21906494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raltegravir-induced DRESS syndrome.
    Loulergue P; Mir O
    Scand J Infect Dis; 2012 Oct; 44(10):802-3. PubMed ID: 22803794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raltegravir-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome - implications for clinical practice and patient safety.
    Perry ME; Almaani N; Desai N; Larbalestier N; Fox J; Chilton D
    Int J STD AIDS; 2013 Aug; 24(8):639-42. PubMed ID: 23970584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case reports: treatment of nevirapine-associated dress syndrome with intravenous immune globulin (IVIG).
    Fields KS; Petersen MJ; Chiao E; Tristani-Firouzi P
    J Drugs Dermatol; 2005; 4(4):510-3. PubMed ID: 16004028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nevirapine-induced rash with eosinophilia and systemic symptoms (DRESS).
    Gill S; Sagar A; Shankar S; Nair V
    Indian J Pharmacol; 2013; 45(4):401-2. PubMed ID: 24014920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis.
    Shaughnessy KK; Bouchard SM; Mohr MR; Herre JM; Salkey KS
    J Am Acad Dermatol; 2010 Feb; 62(2):315-8. PubMed ID: 19665822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiepileptic hypersensitivity and DRESS syndrome due to phenytoin in two pediatric cases.
    Armin S; Chavoshzadeh Z; Mohkam M; Rezaei N
    Turk J Pediatr; 2009; 51(1):76-7. PubMed ID: 19378897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection.
    Santos RP; Ramilo O; Barton T
    Pediatr Infect Dis J; 2007 Nov; 26(11):1053-6. PubMed ID: 17984815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy.
    Bourezane Y; Salard D; Hoen B; Vandel S; Drobacheff C; Laurent R
    Clin Infect Dis; 1998 Nov; 27(5):1321-2. PubMed ID: 9827291
    [No Abstract]   [Full Text] [Related]  

  • 10. Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy.
    Lanzafame M; Rovere P; De Checchi G; Trevenzoli M; Turazzini M; Parrinello A
    Scand J Infect Dis; 2001; 33(6):475-6. PubMed ID: 11450872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolutegravir as a trigger for DRESS syndrome?
    Martin C; Payen MC; De Wit S
    Int J STD AIDS; 2018 Sep; 29(10):1036-1038. PubMed ID: 29621952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [DRESS syndrome as a result of sulfasalazine use].
    van der Mark SC; Segers D; Bakker RC; van Wijngaarden P
    Ned Tijdschr Geneeskd; 2010; 154(18):A2161. PubMed ID: 23134745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review.
    Ganeva M; Gancheva T; Lazarova R; Troeva J; Baldaranov I; Vassilev I; Hristakieva E; Tzaneva V
    Int J Dermatol; 2008 Aug; 47(8):853-60. PubMed ID: 18717872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced hypersensitivity syndrome: drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease.
    Kawakami T; Fujita A; Takeuchi S; Muto S; Soma Y
    J Am Acad Dermatol; 2009 Jan; 60(1):146-9. PubMed ID: 19103366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome.
    Fernando SL
    Australas J Dermatol; 2014 Feb; 55(1):15-23. PubMed ID: 23866082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature.
    Croce F; Vitello P; Dalla Pria A; Riva A; Galli M; Antinori S
    Int J STD AIDS; 2010 Nov; 21(11):783-5. PubMed ID: 21187364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bosentan-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.
    Allanore Y; Moachon L; Maury E; Isvy A; Kahan A
    J Rheumatol; 2010 May; 37(5):1077-8. PubMed ID: 20439535
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe rhabdomyolysis associated with raltegravir use.
    Zembower TR; Gerzenshtein L; Coleman K; Palella FJ
    AIDS; 2008 Jul; 22(11):1382-4. PubMed ID: 18580624
    [No Abstract]   [Full Text] [Related]  

  • 20. Raltegravir, an HIV-1 integrase inhibitor for HIV infection.
    Cabrera C
    Curr Opin Investig Drugs; 2008 Aug; 9(8):885-98. PubMed ID: 18666037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.